Patents by Inventor Jonathan A. Meulbroek

Jonathan A. Meulbroek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180125999
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: November 9, 2017
    Publication date: May 10, 2018
    Inventors: EDWARD B. REILLY, ANDREW C. PHILLIPS, LORENZO BENATUIL, FRITZ G. BUCHANAN, JONATHAN A. MEULBROEK, CHUNG-MING HSIEH, JENNIFER PEREZ
  • Publication number: 20170072065
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 16, 2017
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • Publication number: 20150337042
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 20, 2015
    Publication date: November 26, 2015
    Applicant: ABBVIE INC.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • Publication number: 20110313230
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 22, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Stephen Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan
  • Publication number: 20110293511
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 1, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan, Stephen Stockert
  • Patent number: 6447797
    Abstract: It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: wherein R1 and R2 are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C6 to C20 and R1 and R2 can be the same or different; and R3 to R7 are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R3 to R7 being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: September 10, 2002
    Assignee: Abbott Laboratories
    Inventors: Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Pradip Mukerji, Steven Neal Anderson, Jonathan A. Meulbroek
  • Publication number: 20010026806
    Abstract: It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans.
    Type: Application
    Filed: April 19, 2001
    Publication date: October 4, 2001
    Inventors: Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Pradip Mukerji, Steven Neal Anderson, Jonathan A. Meulbroek
  • Patent number: 6258375
    Abstract: It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: wherein R1 and R2 are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C6 to C20 and R1 and R2 can be the same or different; and R3 to R7 are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R3 to R7 being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: July 10, 2001
    Assignee: Abbott Laboratories
    Inventors: Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Pradip Mukerji, Steven Neal Anderson, Jonathan A. Meulbroek
  • Patent number: 6248372
    Abstract: The present invention is directed to a rice flour extract (RFE) which can be used in the prophylaxis and treatment of bacterial infections, particularly bacterial infections caused by Haemophilus influenzae and to a method of preparing and using such an antibacterial rice flour extract. The anti-Haemophilus influenzae rice flour extract of the present invention can be prepared from commercial food grade rice flours or non-commercial food grade rice flours.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: June 19, 2001
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Steven Neal Anderson, Jonathan A. Meulbroek